// App-Quantinova.ai

3088 : A phase II study of intratumoral administration of the autologous immature dendritic cell (DC) vaccine used after lesion photodynamic therapy (PhDT) and immunomodulation with cyclophosphamide (Cy) in pretreated patients with disseminated malignant melanoma.

Researchers

Presenter

  • Alexey Viktorovich Novik

Principal Investigators

  • Irina Alexandrovma Baldueva

  • Mark Lvovich Gelfond

  • Vladimir Moiseyenko

  • Svetlana Protsenko

  • Tatyana Leonidovna Nehaeva

  • Andrei Ivanovich Waal

  • Eugene Vladimirovich Vorobeychikov

  • Anna Borisovna Danilova

  • Alexey Olegovich Danilov

  • Anna Igorevna Semenova

  • Gulfiya Midhatovna Teletaeva

Medical Centers

  • DTC IIBS, St. Petersburg, Russia

  • NN Petrov Research Institute of Oncology, St Petersburg, Russia

  • NN Petrov Research Institute of Oncology, St Petersburg, Russia

Locations

  • Russia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

Biomarkers

  • Circulating tumor cells

  • ZFP36 Ring Finger Protein Like 1

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved